As of May 24
| +0.04 / +0.74%|
The 3 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 8.00, with a high estimate of 10.00 and a low estimate of 7.00. The median estimate represents a +45.99% increase from the last price of 5.48.
The current consensus among 4 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.